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MacroD1 is a macrodomain containing protein that has mono-ADP-ribose hydrolase
enzymatic activity toward several ADP-ribose adducts. Dysregulation of MacroD1
expression has been shown to be associated with the pathogenesis of several forms of
cancer. To date, the physiological functions and sub-cellular localization of MacroD1 are
unclear. Previous studies have described nuclear and cytosolic functions of MacroD1.
However, in this study we show that endogenous MacroD1 protein is highly enriched
within mitochondria. We also show that MacroD1 is highly expressed in human and
mouse skeletal muscle. Furthermore, we show that MacroD1 can efficiently remove
ADP-ribose from 5′ and 3′-phosphorylated double stranded DNA adducts in vitro.
Overall, we have shown that MacroD1 is a mitochondrial protein with promiscuous
enzymatic activity that can target the ester bonds of ADP-ribosylated phosphorylated
double-stranded DNA ends. These findings have exciting implications for MacroD1
and ADP-ribosylation within the regulation of mitochondrial function and DNA-damage
in vivo.
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INTRODUCTION
ADP-ribosylation is a chemical modification and is involved in the regulation of a
number of processes including stress response, transcription, chromatin structure, DNA
damage repair, cell division and apoptosis (Gibson and Kraus, 2012; Barkauskaite et al.,
2015; Gupte et al., 2017; Palazzo et al., 2017). ARTs are enzymes that synthesize ADP-
ribosylation and, to date, all known ARTs utilize NAD+ as a substrate to transfer ADPr
onto their molecular targets. The known ARTs can be broadly classified into several different
protein families such as (1) ARTDs, also commonly known as PARPs, (2) ARTCs, bearing
a related fold to PARPs, and (3) Sirtuins, a family of NAD+ dependent deacetylases
Abbreviations: ADPr, ADP-ribose; ADPr-phosphate, ADP-ribose-1′′phosphate; AR, androgen receptor; ARH,
ADP-ribosylhydrolase; ART, ADP-ribosyltransferase; ARTC, cholera toxin like ADP-ribosyltransferase; ARTD, diphtheria
toxin like ADP-ribosyltransferases; ENPP, ectonucleotide pyrophosphate/phosphodiesterase; ERα, estrogen receptor
alpha; IMM, inner mitochondrial membrane; IMS, intermembrane space; MAR, mono-ADP-ribose; MART, mono-ADP-
ribosyltransferase; MM, mitochondrial matrix; MTS, mitochondrial targeting sequence; NAD+, β-nicotinamide adenine
dinucleotide; NUDIX, nucleoside diphosphate linked X-moiety hydrolase; OAADPr, O-Acetyl-ADP-ribose; OMM, outer
mitochondrial membrane; PAR, poly ADP-ribose; PARG, poly(ADP-ribosyl) glycohydrolase; PARPs, poly(ADP-ribose)
polymerases; PK, proteinase K; RD, rhabdomyosarcoma; svPDE1, snake venom phosphodiesterase; TARG1, terminal
ADP-ribosyl glycohydrolase 1.
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with some members known to ADP-ribosylate proteins (He et al.,
2012; Dölle et al., 2013; Choi and Mostoslavsky, 2014; Rack et al.,
2015; Gupte et al., 2017; Palazzo et al., 2017).
Poly(ADP-ribose) polymerases are one of the most widely
studied ART groups. In humans, there are 17 different
PARPs with different sub-cellular localizations including plasma
membrane, Golgi, endoplasmic reticulum, nucleus, nucleolus and
cytosol (Leung, 2014; Perina et al., 2014; Vyas et al., 2014; Bock
and Chang, 2016; Abplanalp and Hottiger, 2017). Mammalian
PARPs have been most extensively studied within the context
of DNA repair, however, they have also been implicated in
chromatin remodeling, transcription, unfolded-protein response,
cellular stress response, host–virus interactions and many more
(Gupte et al., 2017). Some members of the PARP superfamily,
such as PARP1/2 and Tankyrases (PARP5a and PARP5b), can
make PAR chains while most other PARP family members have
MART activity (D’Amours et al., 1999; Feijs et al., 2013; Vyas
et al., 2014; Pascal and Ellenberger, 2015).
ADP-ribosylation is a reversible modification and several
hydrolase enzymes have been described that can hydrolyze
ADPr adducts. In mammals, ADP-ribosyl hydrolase enzymes can
be broadly classified into two groups based on their catalytic
domains as (1) macrodomain containing or (2) DraG-like
fold containing hydrolases. Currently, macrodomain containing
hydrolases are the most well characterized and are PARG,
MacroD1, MacroD2 and TARG1. While these belong to the same
family, the have different specificities and reaction mechanisms
(Barkauskaite et al., 2015). PARG is one of the most widely
studied hydrolases and has been shown to rapidly catalyze the
cleavage of PAR chains by hydrolyzing the O-glycosidic bond
between the ADPr units, but is unable to hydrolyze the terminal
ADPr unit linked directly to a protein (Alvarez-Gonzalez and
Althaus, 1989; Lin et al., 1997; Slade et al., 2011; Barkauskaite
et al., 2013). TARG1, MacroD1, and MacroD2 hydrolyze mono-
ADPr (MAR) at glutamic or aspartic acid residues and can
also hydrolyze OAADPr, a by-product of sirtuin activity (Chen
et al., 2011; Peterson et al., 2011; Jankevicius et al., 2013;
Rosenthal et al., 2013; Sharifi et al., 2013; Rack et al., 2016).
ARH 1–3 are mammalian homologs containing the DraG-like
fold. ARH3 has been shown to hydrolyze PAR chains and
OAADPr (Oka et al., 2006; Ono et al., 2006). Recently, ARH3
has been shown to efficiently remove ADP-ribosylation on serine
residues, a modification that is catalyzed by PARP1/HPF1 and
PARP2/HPF1 complexes that regulate genome stability (Gibbs-
Seymour et al., 2016; Bonfiglio et al., 2017; Fontana et al., 2017).
ARH1 specifically removes ADPr from arginine residues (Kato
et al., 2007). Conversely, ARH2 has no known hydrolase activity.
Two additional families of evolutionarily distinct hydrolases are
(1) NUDIX family proteins - hNUDT16 and Escherichia coli
RppH and (2) ENPP family proteins – ENPP1 and svPDE1 can
also catalyze removal of MAR or PAR signal by hydrolysis of
ADPr phosphodiester bonds (Palazzo et al., 2015, 2016; Daniels
et al., 2016). To date, there are few examples of enzymatic reversal
of DNA ADP-ribosylation, DarG antitoxin partner of DarT DNA
ART and PARG in removal of DNA PARylation catalyzed by
PARP1/2 (Jankevicius et al., 2016; Talhaoui et al., 2016). Recently
it has been demonstrated that PARP3 can mono-ADP-ribosylate
double-stranded DNA ends and that several cellular hydrolases,
such as PARG, MACROD2, TARG1, and ARH3, can reverse this
modification (Munnur and Ahel, 2017).
The crystal structure of human ADP-ribosyl hydrolase
MacroD1 (residues 91–325) has been solved and consists of
a macrodomain (residues 151–322) and an N-terminal region
(residues 91–136) rich in basic residues (Chen et al., 2011).
The macrodomain consists of a three-layered α-β-α sandwich
with a central six-stranded β-sheet. Structure-based sequence
alignments indicate that human MacroD1 is highly related to
YmdB protein from E. coli, suggesting that they are functional
and structural homologs (Perina et al., 2014). MacroD1 has been
shown to deacetylate OAADPr, producing ADPr and acetate,
and can also hydrolyze ADPr-1′′phosphate (ADPr-phosphate)
(Neuvonen and Ahola, 2009; Chen et al., 2011). Finally, MacroD1
can hydrolyze MAR but not PAR chains, from PARP1 and
PARP10 automodified proteins in vitro (Barkauskaite et al.,
2013; Jankevicius et al., 2013; Rosenthal et al., 2013). Site-
directed mutagenesis analysis showed that a highly conserved
glycine residue (G270 in humans) is required for both OAADPr
deacetylase and MAR hydrolase activity (Chen et al., 2011;
Barkauskaite et al., 2013). Despite this knowledge of MacroD1
biochemical activities in vitro, the function of MacroD1 in vivo
is yet to be deciphered. Earlier studies have implicated MacroD1
expression (previously known as LRP16 – leukemia related
protein 16) in the pathophysiology of several human cancers
(Xi, 2010; Zhao et al., 2010; Shao et al., 2015). Han et al.
(2003, 2007) showed that estrogen (17β-estradiol) treatment
increased MacroD1 mRNA expression and cell proliferation in
breast cancer MCF-7 cells via ERα activation and that MacroD1
was required for the estrogen-responsive proliferation ability of
MCF-7 cells. Furthermore, it has been shown that MacroD1
physically interacts with ERα (Han et al., 2007). It has also
been suggested that MacroD1 is a co-activator of AR in LNCaP
prostate cancer cells, as binding of MacroD1 to AR (via the
macrodomain) is required to amplify the transcriptional activity
of AR upon androgen treatment (Yang et al., 2009). MacroD1 also
integrates into the NF-κB transcriptional complex by associating
with p65 and is required for NF-κB dependent gene expression
(Wu et al., 2011).
In a previous study, overexpressed C-terminal tagged
MacroD1 was shown to localize to mitochondria, however,
the sub-cellular localization of endogenous MacroD1 is still
unknown (Neuvonen and Ahola, 2009). In this study we aimed
to determine the exact subcellular localization of MacroD1 and
to gain insight into the physiological and cellular function of
the endogenous MacroD1 protein. We show that MacroD1 is
primarily a mitochondrial protein, located within the MM and
that the N-terminal region (residues 1–77) of MacroD1 protein is
required for mitochondrial localization. Furthermore, we show
that MacroD1 is differentially expressed in a tissue-specific
manner in human and mouse tissues and human cancer cell lines.
We show that MacroD1 is highly expressed in skeletal muscle,
a tissue with high mitochondrial content, consistent with a
functional role of MacroD1 within mitochondria in vivo. Finally,
we have biochemically characterized the human MacroD1
protein and, together with the previously published data,
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conclude that MacroD1 is a promiscuous ADPr hydrolase that
removes a wide range of ADP-ribosylated adducts with ester
bonds including proteins, DNAs and small chemical groups
(Rack et al., 2016).
MATERIALS AND METHODS
Immunoblotting
Mouse tissue and human cell protein extractions were performed
using RIPA buffer [150 mM NaCl, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl (pH 8.0)]
supplemented with protease inhibitors (Roche) and phosphatase
inhibitors (Roche). Snap frozen mouse tissues were homogenized
using a MP FastPrep-24 homogeniser (MP Biomedicals).
To ensure equal loading, protein lysate concentrations were
determined using Bio-Rad protein assay dye reagent concentrate
(Bio-Rad) according to the manufacturer’s instructions. Protein
samples were diluted to equal concentrations before addition
of 4 X NuPage LDS sample buffer (Thermo Fisher) and heat
denatured at 98◦C for 5 min. Equal volumes of samples were
loaded onto precast 4–12% Bis-Tris NuPage Polyacrylamide gels
(Thermo Fisher). Electrophoresis was performed for 50 min
at 180 V using the XCell Surelock Mini Cell tank system
(Thermo Fisher) and MOPS running buffer (Thermo Fisher).
Proteins were transferred onto nitrocellulose membranes using
Trans-Blot Turbo Transfer System (Bio-Rad). Commercially
available primary antibodies used: HSP60 (Santa Cruz), DNA
ligase III (Novus Bio), GAPDH (Millipore), ATP5A (Abcam),
MACROD1 (Abcam) and β-tubulin (Abcam). Blocking with
5% Milk PBST for 1 h at RT, primary antibodies were
diluted in 5% Milk-PBST and incubated overnight at 4◦C,
secondary antibodies were diluted in 5% Milk PBST for
1 h at RT.
Plasmids
Human full length MacroD1 was amplified from a human HeLa
cDNA library and cloned into pDONR221 (Thermo Fisher)
entry vector and a N-terminal truncation mutant was generated
the same way by excluding the first 77 amino acids using a
different N-terminal primer. SCO6450 (UniProt: Q9ZBG3) was
cloned from total Streptomyces coelicolor DNA. For transient
transfection in human cells, full-length and truncated MacroD1
pDONR221 vectors were recombined using the Gateway LR
reaction (Thermo Fisher) into the pDEST47 destination vector
for the expression of C-terminal GFP fused proteins in human
cell lines. PARP1 EQ was expressed in pET28 vector and was
purified as previously described (Sharifi et al., 2013). DarT
was expressed in pBAD vector, transformed into BL21 strains,
induced with arabinose and purified using TALON affinity resin
(Clontech) as previously described (Jankevicius et al., 2016).
Macrodomain proteins were expressed in pDEST17 or pET15b
and purified as previously described (Chen et al., 2011).
Human Cell Culture and Imaging
All human cell lines used in this study were cultured in DMEM
(Sigma) supplemented with 10% FBS (Thermo Fisher) and
penicillin/streptomycin (Thermo Fisher) at 37◦C with 5% CO2.
Transient DNA transfections (MacroD1-GFP and177MacroD1-
GFP) were performed using TransIT-LT1 Transfection Reagent
(Mirus Bio) and transient small interfering RNA (siRNA)
transfections (control siRNA, MacroD1 siRNA 1 and MacroD1
siRNA 2) were performed with Lipofectamine RNAiMAX
(Thermo Fisher) each according to the manufacturer’s
instructions. For endogenous imaging of MacroD1, RD
cells were seeded on coverslips in 24-well plates and treated
with control siRNA, MacroD1 siRNA 1 or MacroD1 siRNA 2
for 96 h using Lipofectamine RNAiMAX (Thermo Fisher). Cells
were washed 4 times in PBS and fixed in 4% formalin (Sigma).
Cell coverslips were permeabilized using PBS supplemented
with 0.5% Triton X-100 (Sigma) for 5 min and blocked with
PBS supplemented with 10% goat serum (Sigma) for 1 h before
primary and secondary antibodies were applied each for 1 h.
Nuclei were counterstained with DAPI (Thermo Fisher) for
5 min before imaging. Primary antibodies: ATP5A (Abcam,
ab14748) and MACROD1 (Abcam, ab122688); secondary
antibodies: Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 594
goat anti-mouse (both Thermo Fisher). For MacroD1-GFP and
177MacroD1-GFP localization experiments, U2OS cells were
plated in glass-bottomed 24-well plates before being transfected
with MacroD1-GFP or 177MacroD1-GFP expression vectors
using TransIT-LT1 Transfection Reagent (Mirus Bio) according
to the manufacturer’s instructions for 48 h. Transfected U2OS
cells were then incubated with complete media supplemented
with 100 nM MitoTracker Deep Red FM (Thermo Fisher) for
15 min at 37◦C with 5% CO2 to label mitochondria. Cell nuclei
were counterstained with 1 µg/mL Hoechst 33258 (Thermo
Fisher) diluted in PBS for 30 min at 37◦C with 5% CO2.
Following mitochondrial and nuclear labeling, live cell imaging
was performed at 37◦C with 5% CO2. Images of live and fixed
cells were taken on the Olympus Fluoview FV1000 confocal
microscope using a 100× oil objective.
Mitochondrial Isolations and Proteinase
K Digest
High purity mitochondrial preparations were isolated from HeLa
CC cells using the Qproteome Mitochondrial Isolation Kit
(Qiagen) according to the manufacturer’s instructions. The PK
digest assay was adapted from a protocol previously described
(Aerts et al., 2015). Briefly, HeLa cells were harvested from 15 cm2
dishes and resuspended in isolation Buffer (0.6 M mannitol,
10 mM Tris pH 7.4 and 1 mM EGTA). Cell homogenization
was completed using a glass Teflon Dounce homogenizer. Cell
homogenates were centrifuged at 400 g for 10 min to pellet cell
debris and unbroken cells. The supernatant was then centrifuged
at 11,000 g to pellet the mitochondria and were washed twice with
isolation buffer. A Bradford Assay was performed to determine
mitochondrial protein concentrations. Isolated mitochondria
were pelleted again by centrifugation at 11,000 g and washed
twice with either isolation buffer or hypotonic buffer (2 mM
HEPES, pH 7.4). Triton X-100 was added to a final concentration
of 1% before addition of PK (100 µg/ml) as indicated. All samples
were then incubated on an end-over-end shaker for 15 min at
4◦C. 5 mM PMSF was added to all samples to inhibit PK. NuPage
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LDS sample buffer (Thermo Fisher) was added to each sample
before heat denaturation at 98◦C for 5 min. Immunoblotting was
performed as described above.
MacroD1 Mouse Model
The Macrod1 KO mouse strain was a KOMP-Regeneron
(Velocigene) definitive null design (project ID: VG13617)
whereby exons 1–3 are deleted and replaced with the promoter
driven Zen_Ub1 cassette (flanked by LoxP sites). Mice were
generated by blastocyst injection using a pre targeted ES cell
line ordered from the IMPC (International Mouse Phenotyping
Consortium) (Dickinson et al., 2016). Prior to further analysis
the promoter driven Zen_Ub1 cassette was removed by crossing
onto a Sox2Cre line. All experiments were conducted under the
authority of a valid United Kingdom Home Office Project License
30/3307 and have undergone due ethical review process. Tissue
samples were collected from 11 to 13 weeks old, sex matched mice
and using littermate controls, genetic background is C57BL/6JN
mix.
DNA ADP-Ribosylation and
De-ADP-Ribosylation Assays
ADP-ribosylation of thymidine base on single stranded DNA
(GTGGCGCGGAGACTTTCAGAA) by DarT was performed
as previously described (Jankevicius et al., 2016). ADP-
ribosylation of phosphorylated double stranded DNA ends
was adapted from an earlier study (Talhaoui et al., 2016).
Briefly, double-stranded DNA substrate was prepared by
annealing phosphorylated or non-phosphorylated 21mer oligo
(GTGGCGCGGAGACTTAGAGAA) with annealing partner
40mer (GGAATTCCCCGCGCCAAATTTCTCTAAGTCTCCG
CGCCAC) at 98◦C for 5 min and gradually cooled down to
room temperature. Single-stranded and double-stranded DNA
substrates were ADP-ribosylated in the presence of 1 µM DarT or
PARP1 E998Q, respectively, and 20 mM HEPES-KOH (pH 7.6),
50 mM KCl, 5 mM MgCl2, 1 mM DTT, and 100 µg/ml
BSA, 50 µM NAD (Trevigen) and 50 kBq 32P labeled NAD
(PerkinElmer) per reaction. Modified DNA substrate was treated
with PK and SDS or PARPi (Olaparib) and was used as a substrate
for de-ADP-ribosylation reactions by adding 1 µM hydrolase
enzymes (MacroD1 WT or MacroD1 mutant or SCO6450 or
DarG). DNA ADP-ribosylation was performed at 37◦C for
30 min and de-ADP-ribosylation assay was performed at 30◦C
for 30 min. The samples were loaded on a pre-run denaturing
urea PAGE gel at 10–12 W in 0.5× TBE buffer. The gel was dried
under vacuum and visualized by autoradiography.
RESULTS
MacroD1 Is Highly Expressed in Human
and Mouse Skeletal Muscle
It is not clear how MacroD1 functions in cells. The secondary
and tertiary structures of MacroD1 do not unveil much
information about this protein. The only known domains are
the macrodomain and a predicted MTS at the N-terminus
(Figure 1A). Whilst there is some evidence that MacroD1
expression regulates cell proliferation in human breast cancer
MCF-7 cells, little is known about the physiological role of
MacroD1 in humans. In order to gain insight into the possible
physiological role of MacroD1, we investigated the pattern
of expression in human and mouse tissues. RNA-seq data
from the Genotype-Tissue Expression (GTEx) project1 showed
that MacroD1 was highly expressed in human skeletal muscle
relative to other tissues suggestive of a tissue-specific function
of MacroD1 in skeletal muscle in vivo (Figure 1B). In order
to validate this observation, we analyzed MacroD1 protein
expression in human cell lines and mouse tissues via western blot
analysis. First, we verified the specificity of the antibody using
two different MacroD1 siRNAs (Figure 1C). We then generated
a panel of protein lysates from commonly used human cell lines
to determine whether MacroD1 protein expression is cell line-
specific (Figure 1D). MacroD1 was expressed in all human cell
lines used to varying levels. MacroD1 was highly overexpressed in
the RD cell line, relative to osteosarcoma (U2OS) cells where only
low MacroD1 protein expression was detected. High MacroD1
protein levels in RD cells are further evidence of a possible
(patho)physiological role of MacroD1 in human skeletal muscle.
These data indicate that MacroD1 is differentially regulated and
expressed in different human cell lines and may, therefore, have
cell-type specific functions. Given the marked tissue-specific
pattern of MacroD1 mRNA expression in humans, we sought
to determine whether this was conserved across species and at
a protein level. To do this we extracted protein from wild-type
(Macrod1+/+) and knock-out (Macrod1−/−) mice tissues and
performed immunoblot analysis. Consistent with human mRNA
expression data, Macrod1 steady state protein levels varied greatly
in mouse tissues (Figure 1E). Macrod1 protein was highly
expressed in skeletal muscle consistent with human mRNA
expression data and high protein levels in the human RD cells.
Macrod1 was also expressed in other tissues from Macrod1+/+
mice such as liver and pancreas, albeit at substantially lower levels
(Figure 1E). Conversely we did not detect a MacroD1 band in
white adipose tissue (WAT) or ovarian tissue from Macrod1+/+
mice. Additional bands were detected in both Macrod1+/+ and
Macrod1−/− mouse kidney, spleen and skeletal muscle samples
due to non-specific antibody binding. In Macrod1+/+ BAT, only
a faint band Macrod1 band at 28 kDa was observed. However,
an additional band was observed at a higher molecular weight in
Macrod1+/+ BAT but not in Macrod1−/− BAT. There are several
possible explanations for the additional band in MacroD1+/+
BAT. For example, Macrod1 may be post-translationally modified
in BAT that could influence gel migration. Alternatively, it is
possible that the higher molecular weight band corresponds to
full-length, unprocessed MacroD1 that has retained its MTS.
Furthermore, there may be a splice variant of Macrod1 in BAT
that encodes an additional Macrod1 isoform with a greater
molecular weight. Further experiments would be required to
clarify the identity of this additional band and are beyond the
scope of this study. Overall, these data suggest that the pattern of
MacroD1 expression in human and mouse tissues are conserved,
1www.gtexportal.org
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FIGURE 1 | MacroD1 is differentially expressed in human and mouse. (A) Schematic diagram of human MacroD1 macrodomain. MTS∗ – predicted mitochondrial
targeting sequence using MitoProt II – v1.101 (Claros and Vincens, 1996). (B) RNA-seq analysis of MacroD1 (red) mRNA transcript levels in human tissues.
Data from GTEx (http://www.gtexportal.org). Data shown as median mRNA transcript levels. RPMK – reads per kilobase per million mapped reads. (C) Immunoblot
analysis of MacroD1 steady state protein levels in HeLa cells following 72 or 96 h MacroD1 gene silencing by control siRNA, MacroD1 siRNA 1 or MacroD1 siRNA 2.
(D) Immunoblot analysis of MacroD1 steady state protein levels in human cell lines. (E) Immunoblot analysis of Macrod1 steady state protein levels in tissues from
Macrod1+/+ and Macrod1−/− mice. BAT, brown adipose tissue; WAT, white adipose tissue; short, short exposure time; medium, medium exposure time.
and indicate that MacroD1 likely has a tissue-specific function in
skeletal muscles in vivo.
Endogenous MacroD1 Is Highly Enriched
in Mitochondria
Previous studies addressing MacroD1 function have utilized
MacroD1 overexpression constructs and have documented,
somewhat, opposing conclusions. Several studies have
demonstrated that MacroD1 binds to and regulates several
hormone receptors known to reside within the cytosol and
nucleus. Conversely, another study used a C-terminal tagged
MacroD1 overexpression construct and showed MacroD1
localized to mitochondria (Neuvonen and Ahola, 2009).
Therefore, we sought to determine the subcellular localization
of endogenous MacroD1 in order to gain insight into its
possible physiologically relevant function(s). To do this we
analyzed MacroD1 levels in subcellular fractions from HeLa
cells (Figure 2A). Endogenous MacroD1 was highly enriched in
mitochondrial fractions relative to whole cell lysates, similarly
to the mitochondrial marker ATP5A, showing that endogenous
MacroD1 is highly enriched in mitochondria (Figure 2A). By
comparison MacroD1 steady state protein levels in cytosolic and
nuclear fractions were either comparable to or less than whole cell
extracts (Figure 2A). In order to validate this result and confirm
that endogenous MacroD1 localizes to mitochondria in situ, we
performed indirect immunofluorescence imaging in RD cells
co-stained with MacroD1 and ATP5A1 antibodies (Figure 2B).
To ensure that the MacroD1 antibody used was specific to
native MacroD1, MacroD1 knock-down was performed using
two MacroD1 siRNAs. MacroD1 fluorescence signal was greatly
reduced in RD cells treated with either MacroD1 siRNA 1
or MacroD1 siRNA 2 relative to control siRNA showing
that the antibody used was specific to MacroD1 (Figure 2B).
Furthermore, MacroD1 fluorescence signal highly co-localized
with the mitochondrial marker ATP5A1 (red) in RD cells treated
with siRNA control (Figure 2B). A weak MacroD1 fluorescent
signal was observed within the nucleus of RD cells treated with
control siRNA, MacroD1 siRNA 1 and MacroD1 siRNA 2. There
was no observable difference in the intensity of the nuclear
signal following MacroD1 siRNA knock-down suggestive of
non-specific low level background antibody labeling. However, it
is also possible that a small pool of MacroD1 is located within the
nucleus and has a longer cellular half-life than the mitochondrial
pool of MacroD1, which could also explain the nuclear signal
observed. Nevertheless, this data clearly showed that endogenous
MacroD1 localizes to mitochondria in situ.
The vast majority of the mitochondrial proteome is encoded
by nuclear DNA (nDNA), synthesized in the cytosol and
trafficked to mitochondria. The majority of nDNA encoded
mitochondrial proteins have an N-terminal MTS. The MTS is
required for protein trafficking to mitochondria, recognition and
import by the mitochondrial translocase machinery, and sub-
mitochondrial protein sorting. Mitochondrial proteins destined
for the IMS, IMM, and MM are synthesized as precursor proteins
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FIGURE 2 | Endogenous MacroD1 localizes to mitochondria. (A) Immunoblot analysis of endogenous MacroD1 protein in whole cell extracts (WCE) and cytosolic
[glyceraldehyde 3-phosphate dehydrogenase (GAPDH)], nuclear [DNA ligase 3 (LIG3)], microsomal and mitochondrial [ATP synthase, H+ transporting, mitochondrial
F1 complex, alpha subunit 1, cardiac muscle (ATP5A)] sub-cellular fractions from HeLa cells. (B) Indirect immunofluorescence imaging of RD cells following 96 h
MacroD1 gene silencing by control siRNA, MacroD1 siRNA 1 or MacroD1 siRNA 2 co-stained with MacroD1 (green), ATP5A (red), and DAPI (blue). Scale
bar = 10 µm.
and the N-terminal MTS is cleaved following import (MacKenzie
and Payne, 2007). MacroD1 differs from other macrodomain
proteins, such as MacroD2 and TARG1 (OARD1/C6orf130), as it
has an extended N-terminal sequence. The N-terminal sequence
of MacroD1 contains a predicted MTS and has previously been
shown to be required for mitochondrial localization (Neuvonen
and Ahola, 2009). To confirm that the N-terminus of MacroD1
is required for mitochondrial localization we generated a full-
length MacroD1 overexpression construct (MacroD1-GFP) and
an N-terminal MacroD1 truncation overexpression construct
(177MacroD1-GFP) without the coding sequence for amino
acids 1–77 inclusive, both tagged at the C-terminus with GFP
(Figure 3A). Using three different in silico subcellular localization
prediction programs MitoFates (Fukasawa et al., 2015), TargetP
1.1 (Emanuelsson et al., 2000) and MitoProt II (Claros and
Vincens, 1996), we determined whether the N-terminus of
MacroD1 was predicted to be a MTS (Figure 3B). As expected,
all three servers predicted that MacroD1-GFP contained an
N-terminal MTS with high confidence (Figure 3B). However,
truncation of the N-terminus of MacroD1, as in 177MacroD1-
GFP, was not predicted to contain a MTS in agreement
with the conclusion that the N-terminus of MacroD1 is
required for mitochondrial localization (Figure 3B). We then
transiently transfected U2OS cells with full-length and truncated
MacroD1 overexpression plasmids and assessed trafficking to
mitochondria (MitoTracker) (Figure 3C). MacroD1-GFP was
highly co-localized to mitochondria, however, no mitochondrial
co-localization was observed in cells transfected with the
MacroD1 N-terminal truncation plasmid (Figure 3C). These
results confirm that the N-terminal sequence of MacroD1 is
required for trafficking to mitochondria, consistent with previous
findings by Neuvonen and Ahola, and show that amino acids
1–77 likely contain a MTS (Neuvonen and Ahola, 2009). It is
of note that, similarly to Figure 2B, there is faint MacroD1
nuclear signal in cells transfected with MacroD1-GFP albeit at
a substantially lower intensity than the strong mitochondrial
signal. Overall, based on these experiments, we cannot rule out
the possibility that MacroD1 is present in the nucleus at low
levels, however, we can say with confidence that MacroD1 is
highly enriched within mitochondria in situ.
To test whether MacroD1 is imported into mitochondria or
is bound to the OMM, a PK accessibility assay was performed
(Figure 3D). Isolated mitochondria were treated with PK
in isolation buffer (intact mitochondria) or hypotonic buffer
(mitoplasts) conditions. Hypotonic buffer was used to disrupt
the OMM by osmotic shock making proteins tethered to the
outer leaflet of the IMM and IMS accessible to PK. MacroD1
was protected from PK treatment in both isolation and hypotonic
buffers comparably to the IMM and MM markers UQCRC2
and HSP60, respectively (Figure 3D). In contrast, TOM20,
located at the cytosolic side of the OMM, was degraded by
PK in both isolation and hypotonic buffers and the IMS
protein AIF was only susceptible to PK under hypotonic
buffer conditions. This shows that isolated mitochondria were
intact and treatment with hypotonic buffer made IMS proteins
accessible to PK. Treatment with the detergent Triton X-100
was used to solubilize all mitochondrial membranes making
all mitochondrial markers and MacroD1 susceptible to PK
(Figure 3D). Taken together, this data demonstrates that
MacroD1 is imported into mitochondria and is located within the
IMM or MM.
Activities of MACROD1 on Different
ADP-Ribosylated Substrates
Having established mitochondrial localization of MacroD1, the
next question was its possible physiological activity. Previous
in vitro studies have shown several activities of MacroD1.
MacroD1 can hydrolyze mono-ADP-ribosylated glutamate and
aspartate residues on proteins (Barkauskaite et al., 2013;
Jankevicius et al., 2013; Rosenthal et al., 2013), deacetylate
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FIGURE 3 | The N-terminus of MacroD1 is required for mitochondrial localization and import. (A) Schematic diagram of full-length MacroD1 (MacroD1-GFP) and
N-terminal truncated MacroD1 (177MacroD1-GFP) constructs. MTS∗ – Predicted mitochondrial targeting sequence was ascribed using the MTS cleavage site as
predicted by MitoFates, located between amino acid 77 and 78 (Fukasawa et al., 2015). (B) MTS probability prediction scores for MacroD1-GFP and
177MacroD1-GFP cDNA sequences using MitoFates (Fukasawa et al., 2015), TargetP 1.1 Server (Emanuelsson et al., 2000) and MitoProt II – v1.101 (Claros and
Vincens, 1996). (C) Live cell imaging of U2OS cells transfected with MacroD1-GFP (green) or 177MacroD1-GFP (green) for 48 h; mitochondria and nuclei were
labeled with MitoTracker Deep Red FM (red) and Hoechst 33258 (blue), respectively. (D) Isolated mitochondrial fractions from HeLa cells were resuspended in
isolation buffer or hypotonic buffer (2 mM HEPES) before treatment with proteinase K (PK) and/or Triton X-100 (as indicated). Immunoblot analysis was performed to
determine PK accessibility to MacroD1 and sub-mitochondrial protein markers: AIF [apoptosis-inducing factor 1, mitochondrial; intermembrane space (IMS) marker,
HSP60 (60 kDa heat shock protein, mitochondrial; mitochondrial matrix (MM) marker], UQCRC2 [cytochrome b-c1 complex subunit 2, mitochondrial; inner
mitochondrial membrane (IMM) marker] and TOM20 [mitochondrial import receptor subunit; outer mitochondrial membrane (OMM)] marker. W, whole cell extract; D,
cell debris; P, post mitochondrial supernatant; M, isolated mitochondrial fraction.
OAADPr (Chen et al., 2011) and hydrolyze ADPr-phosphates
(Neuvonen and Ahola, 2009). MacroD1 has many functions
in vitro indicating that it may act as a promiscuous ADPr
hydrolase in vivo, cleansing and recycling cellular ADPr
adducts. In recent years, multiple studies have demonstrated
that certain DNA adducts are a substrate of some ARTs. For
example, the bacterial toxin DarT has previously been shown
to mono-ADP-ribosylate thymidine on single stranded DNA
base in a sequence-specific manner (Jankevicius et al., 2016).
In humans, PARP1 and PARP2 have been shown to ADP-
ribosylate phosphorylated DNA at strand break termini in vitro
(Talhaoui et al., 2016). To further address the promiscuity of
MacroD1 we tested its activity against known ADP-ribosylated
DNA adducts.
First we prepared ADP-ribosylated thymidine on single
stranded DNA, as previously described (Jankevicius et al.,
2016), and tested whether MacroD1 could act on this substrate
(Figure 4A). The single stranded 21mer oligonucleotide used
contained a single DarT modification motif (TNTC). The
21mer substrate oligonucleotide was modified with DarT and
32P NAD+ was used as a radioactively labeled ADPr donor.
32P-labeled 21mer oligonucleotide was used as a size marker
(lane 1). As expected, the 21mer substrate oligonucleotide
was efficiently modified by DarT (lane 2) even following
PK treatment (lane 3) showing that DNA was the substrate
modified by DarT. Consistent with the literature, the bacterial
antitoxin DarG efficiently removed ADPr from the DarT
modified 21mer single stranded DNA substrate (lane 4)
(Jankevicius et al., 2016). Conversely, wild-type MacroD1
(MacroD1 WT), SCO6450 (a macrodomain-containing protein
SCO6450 found in S. coelicolor, a close bacterial homolog of
human MacroD1) and a mutant MacroD1 (lanes 5–7) did
not remove ADPr from DarT modified single-stranded DNA.
These results show that MacroD1 and SCO6450 cannot remove
ADPr from ADP-ribosylated thymidine on single stranded
DNA and that the reversal of this modification is likely
specific to the toxin–antitoxin DarG/DarT system found in
bacteria.
Next we prepared mono-ADP-ribosylated phosphorylated
double stranded DNA ends, as previously described (Talhaoui
et al., 2016) and tested whether MacroD1 could act on
this substrate. ADP-ribosylated phosphorylated double stranded
DNA ends were prepared as previously described with the
following changes (Palazzo et al., 2017). We used the PARP1
E998Q (PARP1 EQ) mutant to specifically introduce MAR
adducts, rather than chains of ADPr, to DNA substrates
(Marsischky et al., 1995; Tao et al., 2009). 32P NAD+ was
used as a radioactively labeled ADPr donor. As for the
DNA substrates, we used double-stranded 5′ (Figure 4B)
or 3′-phosphate (Figure 4C) 21mer oligonucleotide annealed
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FIGURE 4 | MacroD1 and Streptomyces coelicolor protein SCO6450 efficiently remove mono-ADP-ribose adducts from ADP-ribosylated phosphorylated double
stranded DNA ends. (A) De-ADP-ribosylation of ADP-ribosylated thymidine base on single stranded DNA by DarG (lane 4), MacroD1 WT (lane 5), SCO6450 (lane 6),
and MacroD1 mutant (MacroD1 G270E – lane 7) macrodomain-containing proteins. Thymidine base on single stranded DNA was ADP-ribosylated by DarT (lanes
2–8). In both (B,C) phosphorylated (lanes 3–9) double stranded DNA was mono-ADP-ribosylated by PARP1 E998Q. Removal of mono-ADP-ribosylated 5′ (B) and
3′ (C) phosphorylated double stranded DNA ends by MacroD1 WT (lane 6), SCO6450 (lane 7), and MacroD1 mutant (MacroD1 G270E – lane 8) macrodomain
containing protein; ddH2O (lane 5) and BSA (lane 9) were used as negative controls. PARP1 E998Q was unable to ADP-ribosylate non-phosphorylated double
stranded DNA (noP) (lane 2). Mono-ADP-ribosylated phosphorylated double-stranded DNA samples were treated with (lane 3) or without PK (lane 4) to confirm DNA
and not protein was the substrate of PARP1 E998Q modification. 32P radiolabelled 21mer DNA was used as a size marker (M, lane 1 in all experiments). PARPi,
PARP inhibitor; BSA, bovine serum albumin.
with a longer 40mer fragment; as they were shown to be
efficiently modified in vitro (Talhaoui et al., 2016; Palazzo
et al., 2017). As seen in Figures 4B,C, PARP1 EQ only
modified 5′ and 3′-phosphorylated double stranded DNA
ends (lane 3) but not non-phosphorylated double stranded
DNA ends (lane 2). The modified phosphorylated DNA ends
remained intact following PK digest (lane 3) confirming
that DNA modification rather than protein modification.
Importantly, we could demonstrate that wild-type human
MacroD1 (MacroD1 WT) efficiently removes MAR from both
5′ and 3′-phosphorylated-DNA (lane 6), while a catalytic-mutant
form of human MacroD1 (MacroD1 G270E) cannot (lane 8)
(Chen et al., 2011). Together this data shows that MacroD1
can remove mono-ADP-ribosylation from both 5′ and 3′
phosphorylated double stranded DNA, dependent upon the
hydrolase activity of its macrodomain, as recently noted for
several other human ADP-ribosyl hydrolases (Palazzo et al.,
2017). Interestingly, SCO6450, a bacterial homolog of human
MacroD1, also efficiently removed mono-ADP-ribosylation
from 5′ and 3′-phosphorylated DNA substrates (lane 7). The
ability of macrodomain-containing proteins from both human
and bacteria to remove ADPr from phosphorylated double
stranded DNA, indicates that this novel and recently described
function is evolutionarily conserved and possibly of physiological
relevance/importance.
DISCUSSION
Several studies have described nuclear and cytosolic functions
of MacroD1 in vivo. For instance, MacroD1 has been shown
to bind and regulate proteins such as the transcription factors
ERα, AR and NF-κB (Han et al., 2007; Yang et al., 2009; Wu
et al., 2011). More recently, MacroD1 has been shown to bind
and selectively activate, the primarily cytosolic protein (Jeffrey
et al., 1995), Protein Kinase R (PKR) (Li et al., 2017). In this study
we have shown that endogenous MacroD1 is highly enriched
in and primarily localizes to mitochondria. It is, therefore,
unsurprising that MacroD1 is highly expressed in human and
mouse skeletal muscle, a tissue with high mitochondrial content
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and function. Our data is supported by evidence from MitoCarta
and MitoMiner, databases of human nDNA and mtDNA genes
encoding mitochondrial proteins, both categorizing MacroD1 as
a mitochondrial protein (Smith and Robinson, 2009; Calvo et al.,
2016). Furthermore, several independent proteomic analyses
characterizing the mitochondrial proteome reported enrichment
of MacroD1 within mitochondrial fractions, further supportive
of the findings presented within this paper (Lefort et al., 2009;
Rhee et al., 2013). Our data, together with several others, are
consistent with the premise that MacroD1 has a physiological
function within mitochondria in vivo.
Furthermore, we confirm that the N-terminus of
overexpressed MacroD1 is required for mitochondrial
localization, in agreement with previous findings (Neuvonen
and Ahola, 2009). The predicted size of full-length MacroD1
(1–325) is 35.5 kDa. Through the use of two different siRNAs
we validated the specificity of our MacroD1 antibody and
have shown that there is 1 primary isoform of MacroD1
that is approximately 28 kDa in size in all cell lines used.
The difference between the observed and predicted size of
MacroD1 is likely due to cleavage of the N-terminus MTS
following mitochondrial import. MitoProt II predicts that
there is an MTS cleavage site between amino acid 77 and 78
in MacroD1 (Claros and Vincens, 1996). If true, the resultant
cleaved MacroD1 protein would be 250 amino acids long with
a molecular weight of 27.5 kDa, consistent with this hypothesis.
In some previous studies, it is not always clear whether N- or
C-terminal tagged MacroD1 overexpression constructs have
been used during analysis. However, if N-terminal tags were
used, this would disrupt efficient mitochondrial localization
and may account for some of the non-mitochondrial functions
of MacroD1 documented. Having said this, it is also possible
that a small proportion of cellular MacroD1 resides within
the nucleus or cytosol (especially upon some stress) or that
non-mitochondrial isoforms of MacroD1 may be differentially
expressed in a cell line or tissue-specific manner in vivo,
which could also account for these findings. After several
repeated experiments overexpressing MacroD1-GFP in human
cells we can confirm that we always observe some nuclear
signal in this system. Further clarification of the sub-cellular
location of previously reported binding partners of MacroD1
is required in order to establish true physiological relevance
and to conclusively determine whether there is indeed a pool
of MacroD1 within the nucleus or cytosol. Previous studies
have focused on illuminating the association between MacroD1
dysregulation and cancer development. It would be interesting
to determine whether dysregulation of MacroD1 localization
underlies this association which would account for differences
between the findings of this paper and those from previous
studies.
It has only recently been discovered that double stranded
phosphorylated DNA adducts can be ADP-ribosylated by
PARP1/PARP2/PARP3 and de-ADP-ribosylated by several
human macrodomain-containing hydrolases in vitro (Talhaoui
et al., 2016; Munnur and Ahel, 2017; Palazzo et al., 2017).
In this paper we show that MacroD1 can also remove
MAR from phosphorylated double stranded DNA adducts.
The physiological significance of DNA ADP-ribosylation is yet
unknown. It is possible that ADP-ribosylation of DNA is in
fact an off-target activity of PARP family proteins resulting
in DNA lesions in a similar way to the formation of DNA
adenylates produced during abortive DNA ligation events
(Ahel et al., 2006). In both scenarios, 5′phosphorylated DNA
traps a nuclear enzyme to produce nucleotide DNA adducts.
In the case of DNA 5′P adenylates, these are processed by
Aprataxin a DNA repair factor responsible for direct reversal
of these lesions by restoring the conventional 5′P DNA end
which can then be ligated in the presence of the DNA ligase
(Ahel et al., 2006; Rass et al., 2007). If this is indeed true, then
MacroD1 may function in the regulation of mitochondrial
DNA-damage repair by removing ADPr from ADP-ribosylated
DNA adducts.
To date, the only example of reversible DNA ADP-ribosylation
in bacteria comes from the studies of toxin-antitoxin system
(DarT/G) (Jankevicius et al., 2016). SCO6450, a bacterial
homolog of MacroD1 (orthologs of which are also predicted
to exist in most of the bacteria), has comparable hydrolase
activity toward ADP-ribosylated DNA adducts as MacroD1,
suggesting that modification of DNA by ADP-ribosylation
may be a widespread type of signaling in a variety of
organisms.
The question remains, whether MacroD1 performs the
various described enzymatic ADPr hydrolase functions within
mitochondria and if so, which enzyme with ART activity can
generate ADPr adducts in mitochondria. There is currently
limited evidence of ADP-ribosylation within mitochondria.
This is primarily because no member of the PARP family
has been shown to be reside within mitochondria. However,
human Sirtuins 3–5 are known mitochondrial proteins with
deacetylation activity, the product of which is OAADPr (Zhu
et al., 2014). The mitochondrial function of MacroD1 may,
therefore, be paired with protein deacetylation by sirtuins. In
addition to this, SIRT4 has also been suggested to reversibly
mono-ADP-ribosylate glutamate dehydrogenase protein in
mitochondria (Haigis et al., 2006). Furthermore, there is also
some evidence to suggest that non-enzymatic protein ADP-
ribosylation occurs in mitochondria (Hilz et al., 2000).
Together with previous findings, we conclude that, MacroD1
is a promiscuous mitochondrial protein that can remove
MAR from a number of ADP-ribosylated adducts with ester
bonds including ADP-ribosylated phosphorylated double
stranded DNA ends (Neuvonen and Ahola, 2009; Chen
et al., 2011; Jankevicius et al., 2013; Rosenthal et al., 2013).
These findings have exciting implications for MacroD1
and ADP-ribosylation in the regulation of mitochondria
function(s).
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